Pharmacochemical profile of iopromide.
Iopromide (Schering, Berlin) is a new nonionic, monomeric contrast medium containing three different substituents on the triiodinated benzene ring. Iopromide exhibits low osmolality and viscosity in aqueous solutions of high concentrations. It has been shown to have a remarkably low intravenous toxicity in mice and rats. Neural tolerance was found to be equal to or better than that of metrizamide when injected in rats intracisternally and intracerebrally, respectively. The effects of iopromide after selective peripheral and cerebral arterial injections in rats were demonstrated to be very moderate at high dosages. The interaction of iopromide with proteins and membranes was found to be considerably low due to its hydrophilicity. Excretion of iopromide is fast and predominantly by the renal route. On the basis of the preclinical profile iopromide is a very promising contrast agent, being most suitable for all angiographic indications, including digital subtraction angiography, urography, and computed tomography.
D000818:Animals; D001798:Blood Proteins / Q000378:metabolism; D001921:Brain / Q000187:drug effects; D003287:Contrast Media / Q000009:adverse effects* / Q000378:metabolism; D004361:Drug Tolerance; D004912:Erythrocytes / Q000187:drug effects; D006461:Hemolysis / Q000187:drug effects; D006801:Humans; D007463:Iodobenzoates / Q000009:adverse effects*; D007472:Iohexol / Q000031:analogs & derivatives*; D007479:Iopamidol; D007483:Iothalamic Acid / Q000009:adverse effects / Q000031:analogs & derivatives / Q000378:metabolism; D008297:Male; D008793:Metrizamide / Q000009:adverse effects / Q000378:metabolism; D051379:Mice; D051381:Rats; D011919:Rats, Inbred Strains; D014283:Triiodobenzoic Acids / Q000009:adverse effects* / Q000378:metabolism
D001798:Blood Proteins; D003287:Contrast Media; D007463:Iodobenzoates; D014283:Triiodobenzoic Acids; D007483:Iothalamic Acid; D007472:Iohexol; C038192:iopromide; D007479:Iopamidol; D008793:Metrizamide